ArticleEndocrine2025
Impact of dual-release hydrocortisone on disease control and metabolism in congenital adrenal hyperplasia: a retrospective cohort study.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCongenital adrenal hyperplasia (CAH) is an autosomal recessive disorder characterized by impaired cortisol secretion and excess androgen production. The primary treatment for CAH is glucocorticoid (GC) replacement, which is essential to prevent adrenal crises and manage androgen excess. Dual-release hydrocortisone (DR-HC) is a once-daily modified-release formulation of hydrocortisone approved for adrenal insufficiency, which showed to improve the metabolic profile and reduce cardiovascular risk compared to conventional GCs. However, data on its use in CAH patients are scant.
aimTo retrospectively evaluate clinical, metabolic, and hormonal characteristics of CAH patients switched from conventional GC treatment to DR-HC. PATIENTS AND
methodThis retrospective study involved 17 patients (10 males and 7 females) with classic CAH due to 21-OH-hydroxilase deficiency, who were switched to DR-HC. Clinical, metabolic, and hormonal data were assessed at baseline, at six months, and at the last available visit.
resultsPatients showed a tendency to a worse hormonal control, despite an overall increase in daily hydrocortisone equivalent dose; in fact, we observed a trend of increase in androstenedione and 17-OHP levels and a significant deterioration in androstenedione to total testosterone ratio in male (1.37 vs 2.10, p = 0.04); additionally, there was a decrease in the proportion of patients with good disease control [5/17 (29%) vs 1/17 (6%) at last available visit, p = 0.07]. Notably, compared to prior conventional GC regimens total and LDL-c cholesterol levels significantly improved (respectively 178 mg/dL vs 156 mg/dL, p = 0.015 and 101 mg/dL vs 83 mg/dL, p = 0.027), while there were no significant changes in glucose profile. In addition, we did not record any adrenal crises during follow-up; however, unsatisfactory disease control was the primary reason for discontinuation in 11/17 patients after a median duration of 26 months.
conclusionsWhile DR-HC can replicate the circadian rhythm of cortisol secretion, it offers suboptimal hormone control in CAH patients despite increasing HC equivalent doses. Nonetheless, DR-HC is a safe treatment that could improve the metabolic profile compared to conventional GCs. However, DR-HC may be unsuitable in cases requiring tight regulation of androgen excess.
Indexed as
Identifiers
40603719What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.